Arthritis Drug Restores Full Hair in 1 in 5 Severe Alopecia Patients, Trial Finds

Alopecia areata is an autoimmune disease in which the immune system mistakenly attacks hair follicles, causing hair loss ranging from small patches to the entire scalp, eyebrows and body hair, with no reliably effective treatment until now. A pill already approved for various forms of arthritis, upadacitinib, a once-daily oral medication, is offering new hope.

Harvard University researchers ran two large, international Phase 3 clinical trials across hospitals in North America, Europe and China, recruiting severe alopecia areata patients who had lost about 84 percent of their scalp hair on average, some with no regrowth for at least six months. Volunteers took a daily 15mg dose, a 30mg dose, or a placebo. Results were published in the peer-reviewed journal JAMA Dermatology on August 12.

Within 24 weeks, roughly half of those on upadacitinib, both doses combined, saw at least 80 percent of their scalp hair regrow. Over 35 percent of the 15mg group and 46 percent of the 30mg group achieved "deep regrowth" of more than 90 percent coverage. About one in five, or 20 percent, reached a score of zero on the standard hair-loss scale, a completely full head of hair, versus only about 1 percent of the placebo group.

Lead author Arash Mostaghimi, a Harvard professor and associate professor of dermatology at Brigham and Women's Hospital, told Medical News Today on August 24 that the results show "rapid onset and substantial depth of response" and, though not a head-to-head comparison, suggest upadacitinib may be among the most effective systemic treatments evaluated for the condition to date. The drug blocks the JAK/STAT pathway, a cellular signal driving inflammation, letting follicles recover; its safety profile matched prior arthritis use, with no unexpected side effects. It is not a permanent cure and is not yet approved specifically for alopecia areata, but Mostaghimi wrote the two parallel Phase 3 trials showed a positive benefit-risk profile in adults and adolescents with severe disease.